PROGRESS IN NEUROBIOLOGY is a prestigious journal dedicated to advancing the field of neuroscience, published by Pergamon-Elsevier Science Ltd. With an impressive impact factor, it stands as a critical resource for researchers, professionals, and students alike, featuring rigorous peer-reviewed articles that explore the latest developments in neurobiology. The journal has established itself as a leading publication, ranked in the Q1 category for Neuroscience (miscellaneous) and holding a notable 13/113 rank in General Neuroscience per Scopus metrics, placing it in the top 12% of its field. Since its inception in 1959, PROGRESS IN NEUROBIOLOGY has covered a wide array of topics, from molecular mechanisms to cognitive processes, fostering a comprehensive understanding of brain functions. While the journal is not open access, it ensures accessibility to profound knowledge through institutional subscriptions. Researchers and scholars will find critical analyses and innovative research that are pivotal for both foundational knowledge and cutting-edge investigations in the neuroscience realm.

ACTA NEUROBIOLOGIAE EXPERIMENTALIS, an esteemed journal published by the Nencki Institute of Experimental Biology in Poland, has been a pivotal platform for the dissemination of research in the fields of medicine and neuroscience since its inception in 1970. With an ISSN of 0065-1400 and an E-ISSN of 1689-0035, this journal has consistently aimed to contribute to the understanding of neurobiological phenomena, cementing its status within the academic community. Despite its current categorization in the Q3 and Q4 quartiles for Medicine and Neuroscience respectively, ACTA NEUROBIOLOGIAE EXPERIMENTALIS continues to uphold rigorous scientific standards, providing an invaluable resource for researchers, professionals, and students alike. As an essential scholarly outlet, it encourages the exploration of groundbreaking findings and clinical applications in neurobiology, making it an attractive choice for those eager to advance their understanding of this intricate field.

AIMS Neuroscience is an esteemed open-access journal published by the American Institute of Mathematical Sciences (AIMS), dedicated to advancing the field of neuroscience since its inception in 2014. With a robust ISSN of 2373-8006 and an E-ISSN of 2373-7972, this journal aims to provide a platform for innovative research and scholarly discourse that spans the diverse and dynamic landscape of the neuroscience discipline. As of 2023, it holds a respectable Q3 category ranking in the miscellaneous neuroscience field and ranks #65 out of 113 in general neuroscience according to Scopus, positioning it in the 42nd percentile for impact. AIMS Neuroscience encompasses a broad scope of topics, from neurobiology and cognitive neuroscience to computational models and neuroengineering, making it a vital resource for researchers, professionals, and students alike. The journal's commitment to open access ensures that cutting-edge research is freely available, fostering collaboration and knowledge sharing within the global neuroscience community.

METABOLIC BRAIN DISEASE, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal dedicated to advancing our understanding of the metabolic processes impacting brain health and disease. Established in 1986 and set to continue until 2024, this journal encompasses a wide range of interdisciplinary research that intersects the fields of Biochemistry, Cellular and Molecular Neuroscience, and Neurology, as evidenced by its notable quartile placements in Q2 and Q3 for 2023. With an ISSN of 0885-7490 and an E-ISSN of 1573-7365, it serves as a vital resource for researchers and practitioners aiming to deepen their insights into cerebral metabolic disorders and their implications. Although currently not an Open Access option, its rigorous peer-review process ensures that high-quality, impactful research reaches its audience. Showcasing a significant rank within the top percentile of its categories, METABOLIC BRAIN DISEASE is instrumental in shaping the future of neurological research and clinical applications.

NATURE NEUROSCIENCE is a premier journal published by NATURE PORTFOLIO, focusing on cutting-edge research in the field of neuroscience. With an esteemed impact factor that reflects its significance in the academic community, this journal occupies an exceptional place in the 2023 Q1 category for neuroscience (miscellaneous) and boasts a leading Scopus rank of #1 out of 113 in general neuroscience, placing it within the top 1st percentile. Since its inception in 1998, NATURE NEUROSCIENCE has consistently delivered high-quality, peer-reviewed articles that contribute to our understanding of the nervous system, driving innovation and scholarship across disciplines. Although it does not offer open access, the journal remains a vital resource for researchers, professionals, and students seeking to stay at the forefront of neuroscientific discovery and discussion. Its editorial commitment to excellence ensures that it continually shapes the trajectory of neuroscience research well into 2024 and beyond, making it an indispensable asset for anyone passionate about the brain and its complexities.

EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.

ACTA NEUROPATHOLOGICA, published by Springer, is a leading journal in the fields of cellular and molecular neuroscience, clinical neurology, and pathology, recognized for its exceptional quality and impactful research. With an impressive impact factor and currently ranked in the Q1 tier across multiple categories in 2023, this journal serves as a premier platform for the dissemination of groundbreaking findings in neuropathology. The journal's robust Scopus rankings highlight its influence, standing at #2 in Pathology and Forensic Medicine and #5 in Clinical Neurology. Since its inception in 1961, ACTA NEUROPATHOLOGICA has provided crucial insights into neurological diseases and disorders, contributing significantly to the advancement of medical science. Aimed at researchers, practitioners, and students alike, this journal fosters a deeper understanding of neurological conditions and encourages innovative approaches within the field. It is essential reading for anyone dedicated to unraveling the complexities of the nervous system.

eNeuro is a prominent open-access journal published by the Society for Neuroscience, dedicated to advancing the field of neuroscience through the dissemination of high-quality research. Launched in 2015, it reflects its commitment to accessibility by providing a platform for innovative studies and advancements in neurobiology. The journal holds a strong reputation, achieving a Q1 ranking in Medicine (miscellaneous) and a Q2 in Neuroscience (miscellaneous) as of 2023, with Scopus rankings placing it at #56 out of 113 in General Neuroscience, marking it in the 50th percentile. With its convergence to cover articles from 2014 to 2024, eNeuro continues to serve as a vital resource for researchers, professionals, and students alike, offering a comprehensive hub for the latest discoveries and theoretical developments in neuroscience. As part of its mission, eNeuro aims to foster collaboration and inspire the academic community with openly accessible content, making significant contributions to scientific discourse.

NEURAL PLASTICITY is a distinguished open access journal published by Hindawi Ltd, focusing on innovative research in the field of neurology and neuroscience. With its ISSN 2090-5904 and E-ISSN 1687-5443, this journal has been a vital resource for researchers since its inception in 1989, providing high-quality content that bridges the gap between theoretical and clinical aspects of neural plasticity. The journal is recognized with a 2023 category quartile ranking of Q2 in both Neurology and Clinical Neurology, confirming its relevance and impact within the academic community. NEURAL PLASTICITY is ranked 85th out of 400 in Medicine: Neurology (Clinical) and 46th out of 192 in Neuroscience: Neurology on Scopus, placing it in the 78th and 76th percentiles respectively. This makes it a significant platform for publishing cutting-edge research that informs clinical practices and enhances our understanding of neural mechanisms. Researchers, professionals, and students can access a wealth of studies that contribute to the evolving discussion on neural adaptation, recovery, and therapeutic interventions, making NEURAL PLASTICITY an essential addition to the libraries of those dedicated to advancing neurological science.

Purinergic Signalling, published by Springer, is a pivotal academic journal dedicated to the exploration of purinergic signaling pathways and their implications in various biological processes. Since its inception in 2004, the journal has made significant contributions to the fields of Cell Biology, Cellular and Molecular Neuroscience, and Molecular Biology, consistently ranking in the Q3 category in recent assessments. With a strong focus on the molecular mechanisms of purines and their roles in physiology and pathology, Purinergic Signalling serves as an essential resource for researchers and professionals seeking to understand the complexity of cellular communication. Although it does not offer open access, the journal ensures a broad dissemination of high-quality research findings, making it a vital tool for academic advancement in the fields of neuroscience and molecular biology. Its commitment to scholarly excellence is reflected in its Scopus rankings, where it is competitively positioned within its categories. As we approach its 20th anniversary in 2024, Purinergic Signalling continues to inspire and inform cutting-edge research in the dynamic landscape of life sciences.